- * Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.
Introduction to CSL Behring study for Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018 | PHASE 4 | INTERVENTIONAL
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Trial Information
If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Phoenix Children's Hospital
Phoenix,Arizona,United States,85016
Children's Hospital of Los Angeles
Los Angeles,California,United States,90027
University of Iowa Hospitals and Clinics
Iowa City,Iowa,United States,52242
Akron Children's Hospital
Akron,Ohio,United States,44647
Children's Hospital of Philadelphia
Philadelphia,Pennsylvania,United States,19104
Le Bonheur Children's Hospital
Memphis,Tennessee,United States,38105
Neurology Rare Disease Center
Denton,Texas,United States,76208
Children's Specialty Group
Norfolk,Virginia,United States,23507
Seattle Children's Hospital
Seattle,Washington,United States,98105
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov